Iconix Pharmaceuticals, Inc. has announced a major extension of its DrugMatrix® toxicogenomic database to include a large addition of data generated by the Affymetrix GeneChip® platform at the Society of Toxicology Annual Meeting.
The two companies recently signed a collaborative agreement to develop solutions to aid in the study of the toxicological and pharmacological properties of drugs and drug candidates.
According to Iconix, extension of the DrugMatrix database is a key step in this collaboration and will further researchers' ability to effectively prioritize drug candidates and to make decisions earlier in the drug development process.
"The addition of whole genome toxicology information from experiments run on the Affymetrix platform is a major milestone in advancing development of new solutions that will aid in the safety screening of candidate compounds," said Don Halbert, Ph.D., executive vice president of Research and Development at Iconix Pharmaceuticals.
"Equally important, by extending DrugMatrix to include the Affymetrix platform, we are greatly expanding the accessibility and utility of the database."
"We are pleased that Iconix has chosen to add whole genome array data generated by our GeneChip microarray platform to its DrugMatrix database," said Lianne McLean, senior director, Gene Expression Marketing at Affymetrix.
"This information will accelerate toxicogenomic research by helping scientists prioritize compounds at the earliest possible stages."
The DrugMatrix expansion adds data for hundreds of compound treatments in liver, kidney, heart and cultured primary rat hepatocytes. The database now includes data generated by the Affymetrix GeneChip RG-230 2.0 Array.